Citigroup
FBLG icon

Citigroup’s FibroBiologics FBLG Stock Holding History

Citigroup’s Portfolio FBLG Stock Details FBLG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-9
Closed -$106 – 6355
2025
Q2 		$106 Sell
9
-965
-99% -$17.4K ﹤0.01% 5511
2025
Q1 		$17.5K Sell
974
-121
-11% -$3.46K ﹤0.01% 5114
2024
Q4 		$43.8K Buy
1,095
+93
+9% +$4.99K ﹤0.01% 5120
2024
Q3 		$61.9K Buy
1,002
+707
+240% +$47K ﹤0.01% 4955
2024
Q2 		$29.5K Sell
295
-1,226
-81% -$234K ﹤0.01% 4875
2024
Q1 		$329K Buy
+1,521
New +$366K ﹤0.01% 3790

Other funds holding FBLG

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LM
Luminus Management Houston, Texas $166M AUM 75.95% 1-Year Est. Return
YAG
Yorkville Advisors Global Mountainside, New Jersey $155M AUM 58.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Landscape Capital Management Englewood, New Jersey $1.58B AUM 26.88% 1-Year Est. Return
GS
GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return
CFP
Cascade Financial Partners San Diego, California $970M AUM 19.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Citigroup's FBLG Position: Q3 2025 in Review

Citigroup sold out of FibroBiologics (FBLG) in Q3 2025, closing a stake of 9 shares — an estimated $106 sold.

Citigroup first reported a position in FBLG in Q1 2024 and held it in 6 quarters. The position peaked at $329K in Q1 2024. 52 funds tracked by Wall St. Rank hold FBLG as of Q3 2025.

  • Citigroup reported no remaining FibroBiologics position as of Q3 2025 after selling out during the quarter.
  • Citigroup sold 9 FibroBiologics shares in Q3 2025, an estimated $106.
  • Citigroup first reported a position in FibroBiologics in Q1 2024 and held it in 6 quarters.
  • Citigroup's FibroBiologics position peaked at $329K in Q1 2024.
  • 52 funds tracked by Wall St. Rank held FibroBiologics as of Q3 2025.

Based on Citigroup's 13F filing for Q3 2025, filed 10 Nov 2025.